7-氧代-7-苯基庚酸乙酯 | 112665-41-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 7-氧代-7-苯基庚酸乙酯
• 英文名称: ethyl 7-oxo-7-phenylheptanoate
• CAS: 112665-41-5
• 化学式: C₁₅H₂₀O₃
• 分子量: 248.322
• InChiKey: DMINFMRYRQRRTD-UHFFFAOYSA-N

物化性质

• 密度：
  1.034

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-氧代-7-苯基庚酸乙酯 在 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 2.0h， 生成 6-苄酰基己酸
  参考文献：
  名称：

  Structurally Simple Trichostatin A-Like Straight Chain Hydroxamates as Potent Histone Deacetylase Inhibitors

  摘要：

  A series of new, structurally simple trichostatin A (TSA)-like straight chain hydroxamates were prepared and evaluated for their ability to inhibit partially purified human histone deacetylase 1 (HDAC-1). Some of these compounds such as 8m, 8n, 12, and 15b exhibited potent HDAC inhibitory activity with low nanomolar IC50 values, comparable to natural TSA. These compounds induce hyperacetylation of histones in T24 human cancer cells and significantly inhibit proliferation in. various human cancer cells. They also induce expression of p21 and cause cell cycle blocks in human cancer cells. in this paper, we describe the synthesis of these new compounds as well as structure-activity relationship results from enzyme inhibition and alterations in cellular function.

  DOI：

  10.1021/jm020154k
• 作为产物：
  描述：

  庚二酸氢乙酯 在 三氯化铝 、 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 7-氧代-7-苯基庚酸乙酯
  参考文献：
  名称：

  Quinones. 4. Novel eicosanoid antagonists: synthesis and pharmacological evaluation

  摘要：

  A new series of omega-phenyl-omega-quinonylalkanoic acids and related compounds was synthesized. The compounds were tested for their inhibitory effects on U-44069-induced contraction of the rabbit aorta. (+/- )-7-(3,5,6-Trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid (4d) (AA-2414) with pA2 value of 8.28 was one of the most potent compounds. Compound 4d inhibited U-46619-induced contraction of the guinea pig lung (pA2 = 8.29) and U-44069-induced aggregation of the guinea pig platelet (IC50 = 3.5 x 10(-7) M). Compound 4d displaced the binding of [3H]U-46619 to guinea pig platelets (IC50 = 7.4 x 10(-9) M). Compound 4d also showed very potent inhibitory effects with an MED of 0.3 mg/kg (po) on U-46619-, LTD4-, PAF-, or IgG1-induced bronchoconstriction in guinea pigs. The enantiomers of 4d were prepared. The R-(+) isomer 8a was active in both in vitro and in vivo tests, but the S-(-) isomer 8b was much less active. We concluded that the antiasthmatic effects of 4d were based mainly on the TXA2 receptor antagonistic action. In addition, compound 4d showed potent inhibitory effects on PGD2-, PGF2 alpha-, and 11-epi-PGF2 alpha-induced contraction of the guinea pig tracheal strips. The diverse inhibitory effects might be expressed in terms of eicosanoid-antagonistic activity.

  DOI：

  10.1021/jm00129a030

文献信息

• [EN] PYRROLOPYRIDAZINE DERIVATIVES<br/>[FR] DERIVES DE PYRROLOPYRIDAZINE
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2004063197A1

  公开（公告）日：2004-07-29

  The invention relates to compound of the formula (I) or its salt, in which R1, R2, R3 and R4 are as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of PDE-IV or TNF-α mediated diseases.

  这项发明涉及公式（I）的化合物或其盐，其中R1、R2、R3和R4如描述中所定义，它们作为药物的用途，它们的制备过程以及用于治疗PDE-IV或TNF-α介导的疾病的用途。
• Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06251926B1

  公开（公告）日：2001-06-26

  This invention provides a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance.

  本发明提供了一种新颖的氧亚氨基烷酸衍生物，该衍生物具有优异的降糖和降脂作用，用于治疗糖尿病、高脂血症、胰岛素不敏感、胰岛素抵抗和葡萄糖耐量受损。
• Synthesis of β-hydroxy esters using highly active manganese
  作者：YoungSung Suh、Reuben D. Rieke

  DOI：10.1016/j.tetlet.2003.11.045

  日期：2004.2

  A modified Reformatsky reaction is reported using highly reactive manganese (Mn*). The active manganese was found to readily react with α-haloester in the presence of aldehydes and ketones to yield the corresponding β-hydroxy esters. The reaction is carried out at room temperature in the absence of Lewis acid or trapping agents.

  据报道使用高反应性锰（Mn *）进行了改良的Reformatsky反应。发现该活性锰在醛和酮的存在下容易与α-卤代酯反应以产生相应的β-羟基酯。该反应在室温下在没有路易斯酸或捕集剂的条件下进行。
• Indium-Catalyzed Synthesis of Keto Esters from Cyclic 1,3-Diketones and Alcohols and Application to the Synthesis of Seratrodast
  作者：Yoichiro Kuninobu、Atsushi Kawata、Taihei Noborio、Syun-ichi Yamamoto、Takashi Matsuki、Kazumi Takata、Kazuhiko Takai

  DOI：10.1002/asia.200900553

  日期：2010.4.1

  iron(III) triflate, Fe(OTf)3, copper(II) triflate, Cu(OTf)2, and silver(I) triflate, AgOTf, show high catalytic activities. These reactions proceed through the carbon–carbon bond cleavage by a retro‐aldol reaction and were found to be highly regioselective even in the presence of other functional groups. This type of reaction can also be applied to the preparation of the keto esters during the synthesis

  环状1,3-二酮和醇的酯化反应是在几种路易斯酸的存在下进行的。特别是，三氟甲磺酸铟（III），In（OTf）3，三氟甲磺酸铁（III），Fe（OTf）3，三氟甲磺酸铜（II），Cu（OTf）2和三氟甲磺酸银（I）AgOTf高。催化活性。这些反应通过逆向醇醛缩合反应进行碳-碳键裂解，即使在存在其他官能团的情况下，也具有很高的区域选择性。这种类型的反应也可以用于合成塞拉卓斯特期间的酮酯的制备，后者是一种抗哮喘和类二十烷酸拮抗剂。
• Studies on Non-Thiazolidinedione Antidiabetic Agents. 2. Novel Oxyiminoalkanoic Acid Derivatives as Potent Glucose and Lipid Lowering Agents.
  作者：Hiroshi Imoto、Yasuo Sugiyama、Hiroyuki Kimura、Yu Momose

  DOI：10.1248/cpb.51.138

  日期：——

  We previously reported that (Z)-2-4-[(5-methyl-2-phenyl-1, 3-oxazol-4-yl)methoxy]benzyloxyimino}-2-(4-phenoxyphenyl)acetic acid (3) showed potent glucose and lipid lowering effects in genetically obese and diabetic mice, KKAy. This compound also showed transcriptional activity for peroxisome proliferator-activated receptor (PPAR)-γ. We expanded on the structure–activity relationships of oxyiminoalkanoic acid derivatives based on this transcriptional activity (in vitro). Insertion of a carbon chain between the imino carbon and the carboxyl moiety of (Z)-2-4-[(5-methyl-2-phenyl-1, 3-oxazol-4-yl)methoxy]benzyloxyimino}-2-phenylacetic acid (2) resulted in a marked increase in transcriptional activity at PPARγ. In vivo potencies of synthesized compounds, which showed strong functional activity at PPARγ, were tested using KKAy mice. Among these compounds, (E)-4-4-[(5-methyl-2-phenyl-1, 3-oxazol-4-yl)methoxy]benzyloxyimino}-4-phenylbutyric acid (27) exhibited marked glucose and lipid lowering activity while showing no significant body weight gain. Compound (27) (TAK-559) showed favorable pharmacokinetic properties with good absorption and duration, and was considered as an attractive candidate for further evaluation.

  我们之前报道过，(Z)-2-4-[(5-甲基-2-苯基-1,3-恶唑-4-基)甲氧基]苄氧亚胺}-2-(4-苯氧基苯基)乙酸 (3) 在基因肥胖和糖尿病小鼠 KKAy 中表现出显著的降糖和降脂效果。该化合物还显示出对过氧化物酶体增殖物激活受体 (PPAR)-γ 的转录活性。我们基于这种转录活性（体外）扩展了氧亚胺烷酸衍生物的结构—活性关系。在 (Z)-2-4-[(5-甲基-2-苯基-1,3-恶唑-4-基)甲氧基]苄氧亚胺}-2-苯基乙酸 (2) 的亚胺碳与羧基之间插入碳链，显著提高了 PPARγ 的转录活性。合成化合物在 KKAy 小鼠中进行了体内效能测试，这些化合物在 PPARγ 上显示出强的功能活性。在这些化合物中，(E)-4-4-[(5-甲基-2-苯基-1,3-恶唑-4-基)甲氧基]苄氧亚胺}-4-苯基丁酸 (27) 展示了显著的降糖和降脂活性，同时未显示出明显的体重增加。化合物 (27) (TAK-559) 显示出良好的药代动力学特性，具备良好的吸收和持续时间，因此被认为是进一步评估的有吸引力的候选者。